ALKS · Alkermes plc

This 8-K/A reports the consummation of Alkermes’ strategic acquisition of Avadel, a transformative deal that adds LUMRYZ — an FDA-approved treatment for narcolepsy — to Alkermes’ proprietary commercial portfolio and brings a dedicated narcolepsy commercial organization. The $2.307 billion total consideration reflects a premium valuation anchored by LUMRYZ’s strong 2025 performance ($279.1M in net product revenue) and the $1.769 billion fair value assigned to the LUMRYZ intangible asset, which carries a 14-year estimated useful life and will drive $91.8M in annual amortization expense. The transaction was financed entirely through debt: $1.525 billion drawn from newly established senior secured term loan facilities, significantly increasing Alkermes’ leverage and introducing $101.9M in pro forma 2025 interest expense. The CVR structure — $1.50 per Avadel share contingent on a future milestone — introduces upside potential but also uncertainty, as the $165.7M maximum payout hinges on achievement of a yet-unspecified development or regulatory event. Avadel’s 2025 results were materially boosted by a $57.3M litigation settlement gain following resolution of long-running patent disputes with Jazz Pharmaceuticals, including a waiver of royalties on LUMRYZ sales through September 30, 2025. While the acquisition strengthens Alkermes’ position in CNS, the substantial debt load, significant amortization drag, and contingent nature of CVR value create near-term financial headwinds and execution risk around integration and milestone delivery.